

contract proposals and for the critique and evaluation of extramural/intramural programmatic and personnel policies, including consideration of personnel qualifications and performance and the competence of individual investigators. These applications and proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications and proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Carole Frank, the Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630E, 6130 Executive Blvd MSC 7405, Bethesda, Maryland 20892-7405, (301-496-5708) will provide a summary of the meetings and the roster of committee members, upon request.

For other information pertaining to the meetings or individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, contact the contact person indicated below.

Committee Name: Board of Scientific Counselors, Division of Cancer Prevention and Control

Contact Person: Ms. Linda M. Bremerman, Executive Plaza North, Rm 232, Telephone: (301) 496-8526

Date of Meeting: January 19-20, 1995

Place of Meeting: Building 31, Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892

Open: January 19, 1995, 8:30 am to 12 pm, January 20, 10:15 am to adjournment

Agenda: Review progress of programs within the Division and review of concepts being considered for funding.

Closed: January 19, 1995, 3:15 pm to 5 pm

Agenda: Extramural/Intramural programmatic and personnel policies of a sensitive nature and consideration of personnel qualifications and performance and the competence of individual investigators.

Place of Meeting: Building 31, Conference Room 9, 9000 Rockville Pike, Bethesda, MD 20892

Open: January 19, 1995, 1 pm to 3 pm

Agenda: Discuss current and future programs of the subcommittee and review of concepts being considered for funding.

Committee Name: Biometry and Epidemiology Contract Review Committee

Contact Person: Dr. Harvey P. Stein, Room 601c, Executive Plaza North, Telephone: (301) 496-7030

Date of Meeting: February 3, 1995

Place of Meeting: Conference Room G, 6130 Executive Boulevard, Rockville, MD 20852

Closed: February 3, 1995, 9 am to adjournment

Agenda: Review, discussion and evaluation of individual contract proposals.

Committee Name: Subcommittee A of the Cancer Research Manpower and Education Review Committee

Contact Person: Dr. Mary Bell, Room 611A, Executive Plaza North, Telephone: (301) 496-7978

Date of Meeting: February 14-17, 1995

Place of Meeting: The Holiday Inn, 2101 Wisconsin Avenue, NW., Washington, DC 20007

Closed:

February 14, 1995 7:30 pm to recess

February 15, 1995 8 am to recess

February 16, 1995 8 am to recess

February 17, 1995 8 am to adjournment

Agenda: Review, discussion and evaluation of individual grant applications.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: December 27, 1994.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-43 Filed 1-3-95; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Innovative Ventricular Assist System (IVAS)

Date: January 18-19, 1995

Time: 7:30 p.m.

Place: Residence Inn, Bethesda, Maryland
Contact Person: Carl A. Ohata, Ph.D., 5333 Westbard Avenue, Room 5A09, Bethesda, Maryland 20892 (301) 594-7483

Purpose/Agenda: To evaluate and review contract proposals.

Name of SEP: Clinical Center for Etiology of Sarcoidosis: A Case Control Study—Coordinating Center

Date: January 27, 1995

Time: 12:00 p.m.

Place: Holiday Inn, Chevy Chase, Maryland

Contact Person: S. Charles Selden, Ph.D., 5333 Westbard Avenue, Room 552, Bethesda, Maryland 20892 (301) 594-7476
Purpose/Agenda: To evaluate and review contract proposals.

These meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838 Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: December 23, 1994.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-44 Filed 1-3-95; 8:45 am]

BILLING CODE 4140-01-M

Public Health Service

Statement of Organizations, Functions, and Delegations of Authority; Office of the Assistant Secretary for Health

Part H, Public Health Service (PHS), Chapter HA (Office of the Assistant Secretary for Health), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health Services (DHHS) (42 FR 61318, December 2, 1977, as amended most recently at 59 FR 52553-52554, October, 18, 1994) is amended to reflect changes in reporting relationships in the Office of the Assistant Secretary for Health.

Office of the Assistant Secretary for Health

Under *Chapter HA, Office of the Assistant Secretary for Health, Section HA-10, Organization*, delete the list and insert the following:

1. Office of Health Communications (HAB)
2. President's Council on Physical Fitness and Sports (HAC)
3. Office of Research Integrity (HAG)
4. National AIDS Program Office (HAA)
5. Office of Health Legislation (HAJ)
6. Office of Equal Employment Opportunity (HAK)
7. Office of International and Refugee Health (HAL)
8. Office of Minority Health (HAM)
9. Office of the Surgeon General (HAN)

10. Office of Emergency Preparedness (HAP)
11. Office of Management (HAU)
12. Office of Disease Prevention and Health Promotion and Health Planning and Evaluation (HAV)
13. Office on Women's Health (HAW)
14. National Vaccine Program Office (HA2)
15. Office of Population Affairs (HA5)
16. PHS Executive Secretariat (HA6)
17. Office of Intergovernmental Affairs (HA7)

Under *Chapter HA, Section HA-20, Functions*, in the statement for the *Office of Communications (HAB)*, change the title to *Office of Health Communications (HAB)*, delete the first sentence and insert the following:

The Office is under the direction of the Deputy Assistant Secretary for Health (Communications) who advises the Assistant Secretary for Health, through the Principal Deputy Assistant Secretary for Health, on a PHS-wide strategic communications program.

Following the title *President's Council on Physical Fitness and Sports (HAC)*, insert a new first sentence, as follows:

The President's Council on Physical Fitness and Sports is directed by the Executive Director who reports to the Principal Deputy Assistant Secretary for Health.

Following the title *Office of Equal Employment Opportunity (HAK)*, delete the first paragraph and insert the following:

The Director, Office of Equal Employment Opportunity (OEEO), reports to the Principal Deputy Assistant Secretary for Health on EEO policy and on operational matters to the Deputy Assistant Secretary for Health (Management and Budget), who serves as the Director of the PHS Equal Employment Opportunity Program and as the principal advisor on all PHS equal employment matters. The Director, OEEO, serves as Deputy Director of the PHS Equal Employment Opportunity Program to provide functional supervision throughout PHS and to direct OEEO activities.

In the statement for the *Office of Minority Health (HAM)*, delete the first sentence and insert the following:

The Deputy Assistant Secretary for Minority Health serves as the Director of the Office of Minority Health and advises the Assistant Secretary for Health, through the Principal Deputy Assistant Secretary for Health, about health program activities that address minority populations, develops policies for the improvement of the health status of minority populations, and coordinates all PHS minority health activities.

In the statement for the *Office of Emergency Preparedness (HAP)*, delete the first phrase and insert the following:

The Director of the Office of Emergency Preparedness: (1) Advises the Assistant Secretary for Health, through the Principal Deputy Assistant Secretary for Health, on emergency preparedness to:

Following the statement for the *Division of Payment Management (HAU45)*, add the following: *Office of Disease Prevention and Health Promotion and Health Planning and Evaluation (HAV)*. The Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion and Health Planning and Evaluation) serves as the Director of the Office and advises the Assistant Secretary for Health, through the Principal Deputy Assistant Secretary for Health, on health policies, procedures, and activities which relate to disease prevention, health promotion, preventive health services, health information and education, and national health planning and evaluation. The Office provides a program of leadership, coordination and liaison between PHS and other Federal agencies, national non-Federal organizations, State and local agencies and private sector organizations that have roles in disease prevention, health promotion and national health planning. The Office coordinates the development of national health policy, plans, legislative proposals, regulations, and the conduct of health policy analyses and evaluations.

In the statement for the *Office on Women's Health (HAW)*, delete the first sentence and insert a new sentence, as follows:

The Deputy Assistant Secretary for Women's Health, who reports to the Principal Deputy Assistant Secretary for Health, is Director of the Office on Women's Health and serves as advisor on scientific, legal, ethical, and policy issues relating to women's health.

In the statement for the *National Vaccine Program Office (HA2)*, delete the first sentence and insert the following:

The Deputy Director of the National Vaccine Program (NVP) serves as the Director, National Vaccine Program Office, and reports to the Assistant Secretary for Health regarding NVP activities and to the Principal Deputy Assistant Secretary for Health on operational and administrative matters.

Following the statement for the *National Vaccine Program Office (HA2)*, delete the title and statement in their entirety for the *Senior Advisor for Environmental Affairs (HA3)*.

In the statement for the *Office of Population Affairs (HA5)* delete the first paragraph and insert the following:

The Office is under the direction of the Deputy Assistant Secretary for Population Affairs who advises the Assistant Secretary for Health regarding the mandated provisions of Title X, Population Research and Voluntary Family Planning Programs; and Title XX, Adolescent Family Life Demonstration Projects and provisions of Title XVII, Office of Adolescent Health of the Public Health Service Act; and who reports to the Principal Deputy Assistant Secretary for Health concerning other operational and administrative matters.

Following the title *PHS Executive Secretariat (HA6)*, insert a new first sentence, as follows:

The Director of the PHS Executive Secretariat reports to the Principal Deputy Assistant Secretary for Health.

In the statement for the *Office of Intergovernmental Affairs (HA7)*, delete the beginning phrase and insert the following:

The Director of the Office of Intergovernmental Affairs reports to the Principal Deputy Assistant Secretary for Health. The Office:

After the statement for the Office of Intergovernmental Affairs (HA7), delete the titles and statements in their entirety for the *Office of Disease Prevention and Health Promotion (HA8)* and the *Office of Health Planning and Evaluation (HA9)*.

Public Health Service (PHS) Regional Offices

Under *Chapter HD, Section HD-20 Functions*, following the title *Public Health Service (PHS) Regional Office (HD1-HDX)*, delete the first sentence and insert the following:

The Public Health Service (PHS) Regional Offices are headed by Regional Health Administrators (RHA), who report to the Principal Deputy Assistant Secretary for Health and who serve as regional PHS representatives. The RHA directs and administers Regional Office activities and is responsible for integrating health and medical expertise with regional program efforts.

Office of the Assistant Secretary for Health

Under *Chapter HD, Section HD-30, Delegations of Authority*, add the following:

All delegations and redelegations of authority to officers and employees of the OASH which were in effect immediately prior to the effective date of this reorganization will be continued in effect in them or their successors,

pending further redelegation, provided they are consistent with this reorganization.

Donna E. Shalala,

Secretary.

[FR Doc. 95-114 Filed 1-3-95; 8:45 am]

BILLING CODE 4160-17-M

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that

certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are *not* to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACCU-LAB, Inc., 405 Alderson St., Schofield, WI 54476, 800-627-8200 (formerly: Alpha Medical Laboratory, Inc., Employee Health Assurance Group, ExpressLab, Inc.)

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/205-263-5745

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866

Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787

Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444/800-877-7016

Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5810

Center for Laboratory Services, a Division of LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913-888-3927

Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310-215-6020

Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800-445-6917

Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-836-3093

Damon/MetPath, 8300 Esters Blvd., Suite 900, Irving, TX 75063, 214-929-0535 (formerly: Damon Clinical Laboratories)

Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, Great Lakes, IL 60088-5223, 708-688-2045/708-688-4171

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468

Drug Labs of Texas, 15201 I-10 East, Suite 125, Channelview, TX 77530, 713-457-3784

DrugProof, Division of Laboratory of Pathology of Seattle, Inc., 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800-898-0180/206-386-2672 (formerly: Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310

Eagle Forensic Laboratory, Inc., 950 N. Federal Highway, Suite 308, Pompano Beach, FL 33062, 305-946-4324

ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609

General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267

Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800-725-3784/915-563-3300 (formerly: Harrison & Associates Forensic Laboratories)

HealthCare/MetPath, 24451 Telegraph Rd., Southfield, MI 48034, Inside MI: 800-328-4142 / Outside MI: 800-225-9414 (formerly: HealthCare/Preferred Laboratories)

Holmes Regional Medical Center Toxicology Laboratory, 5200 Babcock St., N.E., Suite 107, Palm Bay, FL 32905, 407-726-9920,

Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513-569-2051

Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504-392-7961

Marshfield Laboratories, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/800-222-5835

Med-Chek/Damon, 4900 Perry Hwy., Pittsburgh, PA 15229, 412-931-7200 (formerly: Med-Chek Laboratories, Inc.)

MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38175, 901-795-1515

Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699-0008, 419-381-5213

Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302-655-5227

MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800-832-3244/612-636-7466

Methodist Hospital of Indiana, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317-929-3587

Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800-752-1835/309-671-5199

MetPath, Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 708-595-3888

MetPath, Inc., One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000

Metropolitan Reference Laboratories, Inc., 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293

National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (formerly: Maryland Medical Laboratory, Inc.)

National Health Laboratories Incorporated, 2540 Empire Dr., Winston-Salem, NC 27103-6710, Outside NC: 919-760-4620/800-334-8627 / Inside NC: 800-642-0894

National Health Laboratories Incorporated, d.b.a. National Reference Laboratory,